| Autor: |
Ramirez JA, Angulo FJ, Carrico RM, Furmanek S, Oliva SP, Zamparo JM, Gonzalez E, Zhang P, Parrish LAW, Marimuthu S, Pride MW, Gray S, Matos Ferreira CS, Arnold FW, Istúriz RE, Minarovic N, Moïsi JC, Jodar L |
| Jazyk: |
angličtina |
| Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2023 May; Vol. 29 (5), pp. 919-928. |
| DOI: |
10.3201/eid2905.221618 |
| Abstrakt: |
Although Clostridioides difficile infection (CDI) incidence is high in the United States, standard-of-care (SOC) stool collection and testing practices might result in incidence overestimation or underestimation. We conducted diarrhea surveillance among inpatients >50 years of age in Louisville, Kentucky, USA, during October 14, 2019-October 13, 2020; concurrent SOC stool collection and CDI testing occurred independently. A study CDI case was nucleic acid amplification test‒/cytotoxicity neutralization assay‒positive or nucleic acid amplification test‒positive stool in a patient with pseudomembranous colitis. Study incidence was adjusted for hospitalization share and specimen collection rate and, in a sensitivity analysis, for diarrhea cases without study testing. SOC hospitalized CDI incidence was 121/100,000 population/year; study incidence was 154/100,000 population/year and, in sensitivity analysis, 202/100,000 population/year. Of 75 SOC CDI cases, 12 (16.0%) were not study diagnosed; of 109 study CDI cases, 44 (40.4%) were not SOC diagnosed. CDI incidence estimates based on SOC CDI testing are probably underestimated. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
